These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35642329)

  • 1. DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.
    Jansen K; Kluth M; Blessin NC; Hube-Magg C; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Perez D; Izbicki JR; Jacobsen F; Clauditz TS; Marx AH; Krech T
    Histol Histopathol; 2022 Aug; 37(8):739-748. PubMed ID: 35642329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
    Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
    Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples.
    Jansen K; Farahi N; Büscheck F; Lennartz M; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Jacobsen F; Minner S; Krech R; Clauditz T; Bernreuther C; Dum D; Krech T; Marx A; Steurer S
    Pathol Res Pract; 2021 Dec; 228():153663. PubMed ID: 34717148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
    Li J; Zeng Q; Lin J; Huang H; Chen L
    Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
    Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J
    Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma.
    Bettington M; Walker N; Rosty C; Brown I; Clouston A; McKeone D; Pearson SA; Leggett B; Whitehall V
    Gut; 2017 Jan; 66(1):97-106. PubMed ID: 26475632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation.
    Domingo E; Espín E; Armengol M; Oliveira C; Pinto M; Duval A; Brennetot C; Seruca R; Hamelin R; Yamamoto H; Schwartz S
    Genes Chromosomes Cancer; 2004 Feb; 39(2):138-42. PubMed ID: 14695993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia.
    Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
    World J Gastroenterol; 2013 Aug; 19(32):5286-94. PubMed ID: 23983431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
    Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
    J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coaltered
    Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
    Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness.
    Jansen K; Büscheck F; Moeller K; Kluth M; Hube-Magg C; Blessin NC; Perez D; Izbicki J; Neipp M; Mofid H; Daniels T; Nahrstedt U; Fraune C; Jacobsen F; Bernreuther C; Lebok P; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Marx A; Krech T; Clauditz T
    PeerJ; 2021; 9():e11905. PubMed ID: 34414034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
    Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
    Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.